Clinical Trials Browser

Hodgkin Disease

Multiple Myeloma

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Breast Neoplasms

Breast Neoplasms

Carcinoma, Ovarian Epithelial

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

HER2-positive Breast Cancer

Recurrence, Lymphoma, Large B-Cell, Diffuse

Breast Neoplasms

Unrecognized Condition

Muscle Invasive Bladder Cancer

Lymphoma, T-Cell, Peripheral

Ovarian Neoplasms

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Breast Neoplasms

Breast Neoplasms, Genetic Predisposition to Disease

Ovarian Neoplasms

Lymphoma, T-Cell, Peripheral

Multiple Myeloma

Lymphoma, Large B-Cell, Diffuse

Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms, Recurrence

Leukemia, Plasma Cell, Multiple Myeloma

Breast Neoplasms

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Mesothelioma, Malignant

Breast Neoplasms, Neoplasms

Breast Neoplasms

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Breast Neoplasms

Breast Neoplasms

Clinical Trials

BV-AVD-R Treatment Children Hodgkin's Lymphoma

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

AL3818

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

MITO16MANGO2b

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

easy laugh

Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

Metronomic PLD in Patients With Primary Endocrine Resistant ABC

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

NItCHE-MITO33

Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma

CLIO

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

MITO27

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

PROVE

Bortezomib

Phase II Study in Patients With Operable Breast Cancer

HD-MCL2003

Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma

LITE

A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer